Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ligands for A2B adenosine receptor subtype.

Pier Giovanni Baraldi1, Romeo Romagnoli, Delia Preti

  • 1Dipartimento di Scienze Farmaceutiche, Università di Ferrara, 44100 Ferrara Italy. baraldi@dns.unife.it

Current Medicinal Chemistry
|December 16, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthesis and Pharmacological Characterization of Nociceptin/Orphanin FQ Dimeric Ligands.

Journal of medicinal chemistry·2025
Same author

Sex differences in response to NLRP3 inflammasome blockage in a mouse migraine model: A genetic and pharmacological study.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025
Same author

Design and synthesis of 1,4,8-triazaspiro[4.5]decan-2-one derivatives as novel mitochondrial permeability transition pore inhibitors.

Journal of enzyme inhibition and medicinal chemistry·2025
Same author

Identification of isoxazole-based TRPA1 inhibitors with analgesic effects in vivo.

European journal of medicinal chemistry·2025
Same author

Probing non-peptide agonists binding at the human nociceptin/orphanin FQ receptor: a molecular modelling study.

RSC medicinal chemistry·2025
Same author

PROTAC-ing tuberculosis.

Nature chemical biology·2024

Adenosine interacts with A(2B) receptors, influencing physiological processes like cell growth and inflammation. Selective agonists and antagonists are key for targeting these receptors in conditions such as asthma and diarrhea.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Physiology

Background:

  • Adenosine is a nucleoside with diverse biological effects mediated through four receptor subtypes: A(1), A(2A), A(2B), and A(3).
  • The A(2B) receptor is a low-affinity subtype that couples to adenylyl cyclase stimulation and increases intracellular calcium, impacting various physiological functions.
  • Adenosine acts on A(2B) receptors at concentrations above 10 microM, with these receptors widely distributed, particularly in the colon, bladder, blood vessels, and lungs.

Purpose of the Study:

  • To review the role of adenosine and its A(2B) receptors in physiological regulation.
  • To discuss the development of selective agonists and antagonists for the A(2B) adenosine receptor.
  • To highlight the therapeutic potential of targeting A(2B) receptors in inflammatory and other conditions.

Related Experiment Videos

Main Methods:

  • Literature review of studies on adenosine receptors, focusing on the A(2B) subtype.
  • Analysis of chemical modifications of adenosine to create selective agonists, such as 5'-N-ethylcarboxamidoadenosina (NECA).
  • Examination of xanthine derivatives as classical antagonists for A(2B) receptors.

Main Results:

  • A(2B) receptors regulate smooth muscle cell growth, intestinal function, TNF-alpha inhibition, vascular tone, and inflammatory responses like diarrhea and asthma.
  • NECA is identified as a potent and selective agonist for the A(2B) adenosine receptor.
  • Substituted xanthine analogues are effective classical antagonists for A(2B) receptors.

Conclusions:

  • The A(2B) adenosine receptor plays a significant role in numerous physiological processes and inflammatory conditions.
  • Development of selective agonists and antagonists targeting A(2B) receptors offers therapeutic potential for various diseases.
  • Further research into A(2B) receptor modulation could lead to novel treatment strategies.